Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPG | P10696 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28461987 | 1.00 | ALPG (0.31) | ALPG | |
| SCHEMBL7821 | 1.00 | — | — | |
| SCHEMBL29357 | 1.00 | ALPG (0.31) | ALPG | |
| SCHEMBL277895 | 1.00 | ALPG (0.31) | ALPG | |
| Phosphine SCHEMBL25176319 | 0.93 | — | — | |
| SCHEMBL21044700 | 0.93 | — | — | |
| SCHEMBL6048215 | 0.93 | — | — | |
| SCHEMBL22664583 | 0.93 | — | — | |
| SCHEMBL20556065 | 0.93 | — | — | |
| SCHEMBL8607977 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117716032-A | Target gene iRNA compositions related to metabolic disorders and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-111770923-A | Heterocyclic compound and noxious arthropod control agent containing same | 住友化学株式会社 | 2020-10-13 | — | — | CN | disclosed |
| CN-111712497-A | Heterocyclic compound and noxious arthropod control agent containing same | 住友化学株式会社 | 2020-09-25 | — | — | CN | disclosed |
| CN-111566108-A | Heterocyclic compound and noxious arthropod control agent containing same | 住友化学株式会社 | 2020-08-21 | — | — | CN | disclosed |
| CN-105555279-B | MicroRNA inhibition for treatment of sepsis | 伦敦健康科学中心研究公司 | 2019-12-06 | — | — | CN | disclosed |
| US-10131908-B2 | 5′ phosphate mimics | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20150080457-A1 | 5' PHOSPHATE MIMICS | BANK OF AMERICA, N.A. | 2015-03-19 | — | — | US | disclosed |
| US-8927513-B2 | 5′ phosphate mimics | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20120157511-A1 | 5' PHOSPHATE MIMICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011005860-A2 | 5' PHOSPHATE MIMICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157511-A1 | 5' PHOSPHATE MIMICS | NSUN2, RNGTT, RNMT | ALPG 421/4885 |
| US-20150080457-A1 | 5' PHOSPHATE MIMICS | NSUN2, RNGTT, RNMT | ALPG 433/4885 |
| US-10131908-B2 | 5′ phosphate mimics | NSUN2, RNGTT, RNMT | ALPG 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.